Rapid Improvement in Recalcitrant Cutaneous Juvenile Dermatomyositis With Anifrolumab Treatment-Reference-Cited by-同舟云学术

Rapid Improvement in Recalcitrant Cutaneous Juvenile Dermatomyositis With Anifrolumab Treatment

Published:2023-11-11 Issue: Volume: Page:
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Shaw Katharina S.¹,Reusch Diana B.²,Castillo Rochelle L.²³,Hashemi Kimberly B.²³,Sundel Robert⁴,Dedeoglu Fatma⁴,Vleugels Ruth Ann²³

Affiliation:

1. Section of Dermatology, Department of Dermatology, The Children’s Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia

2. Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

3. Dermatology Program, Division of Immunology, Boston Children’s Hospital, Boston, Massachusetts

4. Rheumatology Program, Division of Immunology, Boston Children’s Hospital, Boston, Massachusetts

Abstract

This case report describes a 14-year-old girl with juvenile dermatomyositis who presented with a 6-year history of a pruritic, photosensitive eruption involving her face, neck, trunk, and extremities and was successfully treated with anifrolumab.

Publisher

American Medical Association (AMA)

Subject

Dermatology

Link

https://jamanetwork.com/journals/jamadermatology/articlepdf/2812109/jamadermatology_shaw_2023_lo_230021_1699635424.98715.pdf

Reference6 articles.

1. Analysis of published criteria for clinically inactive disease in a large juvenile dermatomyositis cohort shows that skin disease is underestimated.;Almeida;Arthritis Rheumatol,2015

2. Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy.;Kim;Curr Opin Rheumatol,2021

3. Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review.;Paik;Clin Exp Rheumatol,2023

4. Assessment of clinical response to anifrolumab in patients with refractory discoid lupus erythematosus.;Shaw;JAMA Dermatol,2023

5. Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers.;Carter;Br J Dermatol,2023

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Innovation in Dermatomyositis;Dermatologic Clinics;2024-09

2. Advances in Juvenile Dermatomyositis: Pathophysiology, Diagnosis, Treatment and Interstitial Lung Diseases—A Narrative Review;Children;2024-08-27

3. Anifrolumab in recalcitrant cutaneous dermatomyositis: A multicenter retrospective cohort study;Journal of the American Academy of Dermatology;2024-08

4. Comment on: Where are we now in biologic drugs for myositis?;Rheumatology;2024-07-18

5. Uso del anifrolumab en el lupus eritematoso sistémico, lupus eritematoso cutáneo y otras dermatosis autoinmunes;Actas Dermo-Sifiliográficas;2024-07